Subscribe
shutterstock_1436567156_jonathan_weiss
Jonathan Weiss / Shutterstock.com
22 March 2022AmericasMuireann Bolger

Takeda, Arbor aim to stop Turkish copies of high blood pressure drug

Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a  generic version of  the blockbuster high blood pressure medication, Edarbi (azilsartan).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Genevant signs $600m liver fibrosis deal with Takeda
18 March 2021   Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Generics
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
1 July 2021   Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
Americas
Third Circuit backs pharma firm in antitrust clash
13 December 2022   Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
Genevant signs $600m liver fibrosis deal with Takeda
18 March 2021   Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Generics
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
1 July 2021   Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
Americas
Third Circuit backs pharma firm in antitrust clash
13 December 2022   Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.

More on this story

Big Pharma
Genevant signs $600m liver fibrosis deal with Takeda
18 March 2021   Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Generics
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
1 July 2021   Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
Americas
Third Circuit backs pharma firm in antitrust clash
13 December 2022   Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility